Brain Diseases: Clinical Trials

582 trials for Brain Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

582 terminated. 582 Phase 2, 88 Phase 1, 56 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2582Terminated 582
Phase 188Terminated 88
Phase 356Terminated 56

Follow Brain Diseases: new trials by email Literature Review of Brain Diseases trials Research Report on Brain Diseases

Trials (filtered) newest first · largest first

All 582 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of GS3-007a for Oral Suspension in the Diagnosis of Adult Growth Hormone Deficiency (AGHD)
GS3-007a dry suspension, Insulin - Adult Growth Hormone Deficiency (AGHD)
Phase 2TerminatedChangchun GeneScience Pharmaceutical Co., Ltd.1202025-12-192026-05-22
ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly
ALXN2420, Placebo - Acromegaly
Phase 2TerminatedAlexion Pharmaceuticals, Inc.82025-10-282026-08-07
A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients With Overt Hepatic Encephalopathy
VS-01 on top of SOC (Active Treatment Group), SOC - Hepatic Encephalopathy, Acute on Chronic Liver Failure (ACLF)
Phase 2TerminatedGenfit32025-08-252026-01-12
An Open-label Extension Safety Study of MELAS Patients Who Completed TIS6463-203 (PRIZM)
zagociguat 15mg - Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)
Phase 2TerminatedTisento Therapeutics372025-08-182026-11-06
A Study of K-645 in the Treatment of Multiple Migraine Attacks
K-645 100 mg, K-645 10 mg, Placebo - Migraine
Phase 2TerminatedTriGemX Bio, Inc.1342025-08-132026-11-05
Extension Study of Participants From SPG302-ALZ-101
SPG302 - Alzheimer's Disease
Phase 2TerminatedSpinogenix122025-03-252025-12-18
Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatic Colorectal Cancer
Tiragolumab, Atezolizumab, Bevacizumab - Microsatellite Stable (MSS) Colorectal Cancer (CRC), Metastatic Colorectal Cancer (CRC)
Phase 2TerminatedUniversity of Colorado, Denver132025-03-252026-11-20
A Phase 1b Study of the NLRP3 Inhibitor VENT-02 in Patients With Mild to Moderate Parkinson's Disease
VENT-02, Placebo - Parkinson Disease
Phase 1 / Phase 2TerminatedVentus Therapeutics U.S., Inc.292025-03-052025-10-29
A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)
MK-1167, Placebo - Alzheimer Disease, Dementia
Phase 2TerminatedMerck Sharp & Dohme LLC3692024-12-162026-07-01
Study of ASN51 in Adults With Early Alzheimer's Disease
ASN51, Placebo - Alzheimer Disease
Phase 2TerminatedAsceneuron S.A.1232024-10-162025-06-29
Ultrasonic Neuromodulation for Treatment of Cognitive Impairment
Diadem prototype - Alzheimer Disease, Dementia
Phase 1 / Phase 2TerminatedUniversity of Utah12024-08-182025-05-25
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures
BHV-7000, Placebo - Generalized Epilepsy
Phase 2 / Phase 3TerminatedBiohaven Therapeutics Ltd.272024-06-202026-03-24
Safety and Pharmacodynamics of SHR-1707 in Alzheimer's Disease Patients
SHR-1707, SHR-1707 placebo - Alzheimer's Disease
Phase 2TerminatedShanghai Hengrui Pharmaceutical Co., Ltd.462024-02-052026-05-13
Intranasal Ketorolac Trial
Ketorolac, Prochlorperazine, Diphenhydramine - Headache, Migraine
Phase 2TerminatedWashington University School of Medicine412024-01-012026-01-16
Insulin-sensitizing NE3107 in Improving Sleep and Fatigue in Subjects With Traumatic Brain Injury
NE3107 - Traumatic Brain Injury
Phase 2TerminatedNeurological Associates of West Los Angeles42023-12-212025-07-25
A Phase 2, Randomized, Prospective Double-Blind, Single-Center, Placebo-controlled Study to Evaluate Safety, Tolerability, Target Engagement, and Efficacy of PrimeC in Patients With Mild to Moderate Alzheimer's Disease.
PrimeC, Placebo - Alzheimer Disease
Phase 2TerminatedNeuroSense Therapeutics Ltd.82023-11-192026-04-09
Maimonides Minocycline in Stroke Study
Minocycline - Stroke, Acute, Ischemic Stroke
Phase 2 / Phase 3TerminatedMaimonides Medical Center22023-11-012025-12-17
High-Dose Ambroxol in GBA1-Related Parkinson
Ambroxol Hydrochloride - Parkinson Disease, GBA Gene Mutation
Phase 1 / Phase 2TerminatedAgyany Pharma LTD462023-10-242026-11-09
Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease
GSK4527226, Placebo - Alzheimer's Disease
Phase 2TerminatedGlaxoSmithKline3672023-10-202026-09-17
Study to Evaluate the Efficacy and Safety of Staccato Apomorphine (AZ-009) in Patients With Parkinson's Disease Experiencing OFF Episodes
Apomorphine Cartridge - Parkinson Disease
Phase 2TerminatedAlexza Pharmaceuticals, Inc.82023-09-272025-10-21

Showing 20 of 582. Sign in to see all of them.

Narrower conditions

Brain Neoplasms (117)  ·  Alzheimer Disease (84)  ·  Stroke (60)  ·  Parkinson Disease (50)  ·  Glioblastoma (42)  ·  Ischemic Stroke (33)  ·  Glioma (28)  ·  Epilepsy (24)  ·  Dementia (23)  ·  Astrocytoma (20)  ·  Brain Injuries, Traumatic (19)  ·  Gliosarcoma (19)  ·  Melanoma (18)  ·  Migraine Disorders (17)  ·  Neoplasm Metastasis (16)

Broader conditions

Nervous System Diseases (575)  ·  Central Nervous System Diseases (574)  ·  Neurodegenerative Diseases (162)  ·  Pathological Conditions, Signs and Symptoms (149)  ·  Neoplasms by Site (138)  ·  Nervous System Neoplasms (136)  ·  Neoplasms (135)  ·  Cardiovascular Diseases (127)  ·  Vascular Diseases (125)  ·  Central Nervous System Neoplasms (123)  ·  Cerebrovascular Disorders (119)  ·  Mental Disorders (117)  ·  Neurocognitive Disorders (107)  ·  Dementia (86)

Interventions

Temozolomide (21)  ·  Bevacizumab (11)  ·  Radiotherapy (7)  ·  Saline Solution (7)  ·  Donepezil (6)  ·  Cannabidiol (5)  ·  Capecitabine (5)  ·  Sodium Chloride (5)  ·  pasireotide (5)  ·  Carboplatin (4)  ·  Erlotinib Hydrochloride (4)  ·  Magnetic Resonance Spectroscopy (4)  ·  Nivolumab (4)  ·  Radiation (4)  ·  Radiosurgery (4)

Sponsors

Pfizer (16)  ·  National Cancer Institute (NCI) (12)  ·  Novartis Pharmaceuticals (11)  ·  Merck Sharp & Dohme LLC (10)  ·  GlaxoSmithKline (7)  ·  Biogen (6)  ·  Eisai Inc. (6)  ·  Johns Hopkins University (6)  ·  Neurocrine Biosciences (6)  ·  AbbVie (5)  ·  Ipsen (5)  ·  M.D. Anderson Cancer Center (5)  ·  Wave Life Sciences USA, Inc. (5)  ·  Columbia University (4)  ·  Duke University (4)

Countries

United States (401)  ·  Canada (84)  ·  United Kingdom (77)  ·  Germany (75)  ·  France (72)  ·  Spain (61)  ·  Italy (50)  ·  Australia (49)  ·  Belgium (33)  ·  Netherlands (33)  ·  Poland (28)  ·  Japan (22)  ·  Israel (20)  ·  South Korea (18)  ·  Sweden (17)

Top investigators

Ahmed Elkashef, MD (2)

Results publications

PMID 29480210, PMID 32250312, PMID 40603145, PMID 12411660, PMID 12749708, PMID 15014939, PMID 15791633, PMID 16648043, PMID 16673051, PMID 17143244, PMID 17188664, PMID 17470830, PMID 17881719, PMID 18234750, PMID 18413464, PMID 18418368, PMID 19654233, PMID 20042969, PMID 20185783, PMID 20571524, PMID 20634684, PMID 21419704, PMID 21468088, PMID 21565557, PMID 21586746, PMID 21700934, PMID 21784661, PMID 21865400, PMID 21873264, PMID 22198309, PMID 22340437, PMID 23615499, PMID 23622977, PMID 23686372, PMID 23733308, PMID 23943316, PMID 24045608, PMID 24152824, PMID 24207098, PMID 24363954, PMID 24412048, PMID 24588854, PMID 24691436, PMID 25090617, PMID 25107879, PMID 25669746, PMID 25671797, PMID 25689146, PMID 25803346, PMID 25973909

NIH funding

2015 (11), 2017 (9), 2009 (8), 2016 (8), 2008 (5), 2014 (5), 2018 (5), 2019 (5), 2005 (2), 2023 (2), P50NS044148 (2), U01CA137443 (2), 1UF1AG046150-01 (1), 2004 (1), 2025 (1)